Volume-9 , Issue-3 , Jun 2022, ISSN 2347-7520 (Online) Go Back

• Open Access   Article

  Efficacy, Reliability and Potential Side Effects Reported from Selected Covid-19 Vaccination Trials

  Rajavi Karaveershettar

  Review Paper | Journal-Paper (IJSRBS)

  Vol.9 , Issue.3 , pp.62-68, Jun-2022

  Abstract

  Full-Text HTML

  References

  Citation

  Abstract
  The COVID-19 disease arisen in Wuhan on December-2019 and was avowed as a contagion. Globally, at present, there have been 517,648,631 verified cases of COVID-19, including 6,261,708 deceased, reported to WHO. The scientific focus on vaccine development has become the ultimatum of the global community. Vaccination is the process of administering a vaccine to develop a defense mechanism against an infection with the help of hosts immune system. The types include protein subunit, RNA-based, non-replicating and replicating virus-like particle, viral vector, live-attenuated virus, replicating bacterial vector, inactivated virus. Though the vaccine has unparallel benefits it also has potential side effects such as thrombocytopenia, anaphylaxis, local side effects, neurological effects, orofacial effects, effects in cancer patients, effects on women due to estrogen, shingles and associated vasculitis and glomerulonephritis. Thus, it is of paramount importance to evaluate the vaccine safety, including the side effects. The objective of this article is to present an information of the adverse side effects of COVID-19 vaccination.

  Key-Words / Index Term
  Covid-19, Corona virus, Vaccination, Vaccine, mRNA.

  References
  [1] N. A. Mustafida, Diyantoro, A. S. Sundari, D. W. Indriati, “Prevalence of Diabetes Mellitus Comorbidity in COVID-19 Patients Treated at Selected Hospital in Surabaya,” International Journal of Scientific Research in Biological Sciences, Vol.9, Issue.1, pp.32-34, 2022.
  [2] A. K. Dutta. “Vaccine against Covid-19 disease–present status of development”, The Indian Journal of Pediatrics, Vol. 87, Issue. 10, pp.810-6, 2020.
  [3] M. Keerthana, P, Chitra., “A study on natural phytochemicals and antiviral drugs to combat the deadly covid-19- an in silico approach,” International Journal of Scientific Research in Biological Sciences, Vol.7, Issue.3, pp.74-78, 2020.
  [4] WHO, (2019). “situation reports Available at: https://www.who. int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed April, 5, 2020.
  [5] M. Qasim, W. Ahmad, M. Yoshida, M. Gould, & M. Yasir. “Analysis of the worldwide corona virus (COVID-19) pandemic trend; a modelling study to predict its spread”, MedRxiv. 2020.
  [6] M. D. Oh, W. B. Park, S. W. Park, P. G. Choe, J. H. Bang, K. H. Song, & N. J. Kim. “Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea”, The Korean journal of internal medicine, Vol.33, Issue.2, pp.233, 2018.
  [7] J. F. W. Chan, S. Yuan, K. H. Kok, K. K. W. To, H. Chu, J. Yang, & K. Y. Yuen. “A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster”, The lancet, Vol. 395, No.10223, pp.514-523, 2020.
  [8] G. Swetha, S. L. Rani, & M. P. Brundha. “Awareness of the side effects of vaccination among general public”, Drug Invention Today, Vol. 14, Issue. 3, 2020.
  [9] M. M. M. Hatmal, M. A. Al-Hatamleh, A. N. Olaimat, M. Hatmal, D. M. Alhaj-Qasem, T. M. Olaimat & R. Mohamud. “Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects:,. Vaccines, Vol. 9, Issue. 6, pp. 556, 2021.
  [10] T. Shimabukuro & N. Nair. “Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine”, Jama, Vol. 325, Issue. 8, pp.780-781, 2021.
  [11] H. Omeish, A. Najadat, S. Al-Azzam, N. Tarabin, A. Abu Hameed, N. Al-Gallab, & M. A. Aldeyab. “Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study”, Human Vaccines & Immunotherapeutics, pp.1-8, 2021.
  [12] S. Xia, K. Duan, Y. Zhang, D. Zhao, H. Zhang, Z. Xie, & X. Yang. “Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials”, Jama, Vol. 324, Issue. 10, pp. 951-960, 2020.
  [13] S. Xia, Y. Zhang, Y. Wang, H. Wang, Y. Yang, G. F. Gao, & X. Yang. “Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial”, The Lancet Infectious Diseases, Vol. 21, Issue. 1, pp.39-51, 2021.
  [14] Tarawneh, & H. Tarawneh. “Immune thrombocytopenia in a 22?year?old post Covid?19 vaccine”, American journal of hematology. 2021.
  [15] E. J. Lee, D. B. Cines, T. Gernsheimer, C. Kessler, M. Michel, M. D. Tarantino, & J. B. Bussel. “Thrombocytopenia following Pfizer and Moderna SARS?CoV?2 vaccination”, American Journal of Hematology. 2021.
  [16] N. G., Kounis, I., Koniari, C., de Gregorio, D., Velissaris, K., Petalas, A., Brinia, & M. Y. Hung. “Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations”, Vaccines, Vol. 9, Issue. 3, pp.221, 2021.
  [17] J. de Vrieze. “Suspicions grow that nanoparticles in Pfizer’s COVID-19 vaccine trigger rare allergic reactions”, Science, Vol. 10, 2020.
  [18] Torjesen. “Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. Bmj, 2021.
  [19] Wise. “Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots”. Bmj, 2021.
  [20] Greinacher, T. Thiele, T. E. Warkentin, K. Weisser, P. A. Kyrle, & S. Eichinger. “Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021. “in press”.
  [21] N. H. Schultz, I. H. Sorvoll, A. E. Michelsen, L. A. Munthe, F. Lund-Johansen, M. T. Ahlen, & P. A. Holme. “Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination”, New England journal of medicine, Vol. 384, Issue. 22, pp. 2124-2130, 2020.
  [22] Soltani Hekmat, & K. Javanmardi. “Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women Receiving Estrogen”, BioMed Research International, 2021.
  [23] S. Furness, H. Roberts, J. Majoribanks, E. Lethaby, M. Hickey, & C. Farquhar. “Hormone therapy in postmenopausal women and risk of endometrial hyperplasia”, Cochrane Database of Systematic Reviews. Vol. 3, 2004.
  [24] S. Waheed, A. Bayas, F. Hindi, Z. Rizvi, & P. S. Espinosa. “Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine”,. Cureus, Vol. 13, Issue. 2, 2021.
  [25] S. Matarneh, A. H. Al?battah, K. Farooqui, M. Ghamoodi, & M. Alhatou. “COVID?19 vaccine causing Guillain?Barre syndrome, a rare potential side efect”, Clinical Case Reports, Vol. 9, Issue. 9, 20201.
  [26] F. Z. Simnani, D. Singh, & R. Kaur. “COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review”, 3 Biotech, Vol. 12, Issue. 1, pp.1-30, 2022.
  [27] M. T. Shakoor, M. P. Birkenbach & M. Lynch. “ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine”, American Journal of Kidney Diseases, Vol. 78, Issue. 4, pp. 611-613, 2021.
  [28] D. Funk, C. Laferrière, A. Ardakani. “A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic”, Frontiers in pharmacology, Vol. 11, pp. 937, 2020.

  Citation
  Rajavi Karaveershettar, "Efficacy, Reliability and Potential Side Effects Reported from Selected Covid-19 Vaccination Trials," International Journal of Scientific Research in Biological Sciences, Vol.9, Issue.3, pp.62-68, 2022